All-Star CEOs Discuss Pricing, But Come Up Short On Solutions
Executive Summary
"Unless we make changes in the system people won’t be able to afford" drugs coming out of our pipelines, Merck’s Frazier says; Pfizer’s Read contends competition is best way to curtail prices.
You may also be interested in...
Impax Buyouts Add Plant, Portfolio And Pipeline
By acquiring three interrelated, privately held companies, Impax adds several branded and generic products, a substantial generic pipeline and an FDA-licensed manufacturing site in New Jersey.
Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.